About Actym Therapeutics
Actym Therapeutics is a company based in Berkeley (United States) founded in 2017 by Christopher Thanos and Laura Hix Glickman.. Actym Therapeutics has raised $59.5 million across 2 funding rounds from investors including Korea Investment Holdings, Boehringer Ingelheim Venture Fund and Illumina Ventures. The company has 7 employees as of December 31, 2024. Actym Therapeutics offers products and services including STACT Platform and ACTM-838. Actym Therapeutics operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Berkeley, United States
- Employees 7 as on 31 Dec, 2024
- Founders Christopher Thanos, Laura Hix Glickman
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$59.5 M (USD)
in 2 rounds
-
Latest Funding Round
$25.5 M (USD), Series A
Oct 18, 2023
-
Investors
Korea Investment Holdings
& 5 more
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Actym Therapeutics
Actym Therapeutics offers a comprehensive portfolio of products and services, including STACT Platform and ACTM-838. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered bacterial vehicle for targeted therapeutic delivery.
Investigational treatment for advanced solid tumors in trials.
Funding Insights of Actym Therapeutics
Actym Therapeutics has successfully raised a total of $59.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $25.5 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $25.5M
-
First Round
First Round
(08 Apr 2020)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - Actym Therapeutics | Valuation | Boehringer Ingelheim Venture Fund , Illumina Ventures | |
| Apr, 2020 | Amount | Series A - Actym Therapeutics | Valuation | Boehringer Ingelheim Venture Fund , Panacea Venture |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Actym Therapeutics
Actym Therapeutics has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Korea Investment Holdings, Boehringer Ingelheim Venture Fund and Illumina Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Founded Year | Domain | Location | |
|
Health tech startups are invested in by Illumina Ventures.
|
Founded Year | Domain | Location | |
|
A life sciences venture fund is operated with global reach.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Actym Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Actym Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Actym Therapeutics Comparisons
Competitors of Actym Therapeutics
Actym Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Actym Therapeutics
Frequently Asked Questions about Actym Therapeutics
When was Actym Therapeutics founded?
Actym Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is Actym Therapeutics located?
Actym Therapeutics is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Who is the current CEO of Actym Therapeutics?
Christopher Thanos is the current CEO of Actym Therapeutics. They have also founded this company.
Is Actym Therapeutics a funded company?
Actym Therapeutics is a funded company, having raised a total of $59.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $34M, raised on Apr 08, 2020.
How many employees does Actym Therapeutics have?
As of Dec 31, 2024, the latest employee count at Actym Therapeutics is 7.
What does Actym Therapeutics do?
Actym Therapeutics was founded in 2017 and is based in Berkeley, United States. Operations are centered in the biotechnology sector, where immune therapy systems are developed to address unmet medical needs. Leadership is provided by co-founders Christopher Thanos as CEO and Laura Hix Glickman as VP. Focus is placed on innovative approaches to immune modulation, with activities conducted through research and development in the therapeutic domain.
Who are the top competitors of Actym Therapeutics?
Actym Therapeutics's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does Actym Therapeutics offer?
Actym Therapeutics offers STACT Platform and ACTM-838.
Who are Actym Therapeutics's investors?
Actym Therapeutics has 6 investors. Key investors include Korea Investment Holdings, Boehringer Ingelheim Venture Fund, Illumina Ventures, Panacea Venture, and GKCC.